A Paradigm Shift in Primary Open Angle Glaucoma by Eltis, Mark
vol 74  |  no 1  |  2012C a n a d i a n J o u r n a l o f o p t o m e t r y | r e v u e C a n a d i e n n e d ’ o p t o m é t r i e 33
by MarK ELtiS, oD, Faao
Introduction 
Glaucoma is a chronic irre-versible neurodegenerative
disease characterized by destructive
changes in the optic nerve head 
and retinal nerve fibre layer due to 
loss of  retinal ganglion cells and 
their axons.1-14
For years glaucoma was consid-
ered to be a disease of  ocular hyper-
tension (greater than 21 mmHg).15-17
Over the last decade the disease has
been redefined as an optic neurop-
athy with field loss resulting from 
IOP unacceptably high for the optic
nerve head.6,8,18-21 Therefore, the sim-
plistic cut-off  point of  21 mmHg
seems outdated and invalid.8,19,22
Despite the prevalence of  glau-
coma, a universal definition of  the
disease is still absent.23-27
Glaucoma is a leading cause of
blindness worldwide and the leading
cause of  vision loss in the United
States.4,6,15,16,25 Approximately 2% of
the U.S. population older than 40
have glaucoma and, with the aging
of  the population, the number of
patients with the disease is expected
to increase.2,15,16,25 Glaucomatous
neuropathy is generally an insidious
disease with no symptoms until the
advanced stages.2,14,28 There is a large
body of  evidence to suggest that
an estimated 50% of  those with glau-
coma have not been diagnosed.6,28
Primary open angle glaucoma
(POAG), the most common glau-
coma29,30 (representing 90-95% of
cases),2 is defined by optic neuropa-
thy in the absence of  an identifi-
able secondary cause.1,2,4,6,21 POAG
is a bilateral condition, but disease
progression may be asymmetric.2,16
POAG can be divided into high ten-
sion glaucoma (HTG) and normal 
tension glaucoma (NTG).30-32 
Although it is frequently accom-
panied by increased IOP, POAG
can exist in patients with normal
IOP.2,15,16 Up to 50% of  patients with
glaucoma never have an IOP above
the statistical norm.22,31,33 Therefore,
IOP alone is not reliable for glau-
coma screening.30,33 However, IOP
remains the only modifiable risk
factor.12,22 Early detection is critical to
prevent permanent structural dam-
age and irreversible vision loss.2,3,28,34
Over the past decade, the diagnosis
and management of  glaucoma have
changed dramatically.15,16 Numerous
advances, such as the diagnostic role
of pachymetry,35,36 imaging devices,37-41
advanced perimeters42-44 and new
therapeutic options,45-47 have revolu-
tionized the diagnosis and manage-
ment of  the disease.3
Case Report 
A 68-year-old female retiree of
Hispanic descent presented to our
office on July 8, 2009 for a routine
exam. She was not satisfied with the
quality of  her old glasses and wanted
to update her prescription. She was
not taking any medication and had
no history of  health problems either
in general or specifically of  the
eye. The patient had neither worn
contact lenses nor had any corrective
surgery. The patient had no known
allergies and was not aware of  health
conditions in her family, was neither
a smoker nor a drinker and did not
engage in recreational drug use.
Presenting distance visual acuities
through her glasses (+3.25 - 2.00
× 065 OD and +3.25 - 2.00 × 120
OS) were 20/40 OD, 20/20 OS and
20/20 OU. She was wearing progres-
sive addition lenses, and her vision
through her +2.25 reading addi-
tion was 20/30 OD, 20/20 OS and
20/20 OU (40 cm working distance).
Extraocular muscles were un-
restricted in all gazes. Pupils were
round and reactive to light and ac-
commodation with negative Marcus
Gunn. Confrontation visual fields
were full to finger count in both
eyes, and near point of  convergence
was 8 cm. Cover test was ortho in
the distance and at near.
Subjective refraction was OD
+2.25 - 2.00 × 061 20/25 and OS
+3.25 - 2.00 × 120 20/20. Her new
add was +2.50.
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Slit lamp examination revealed
normal lids and lashes. The conjunc-
tivas of  both eyes were clear. Both
corneas had arcus senilis present
but were otherwise clear and did not
stain with fluorescein. Irises were
brown, and transillumination was
absent in both eyes. Both crystalline
lenses had grade 1 cortical spoking
and nuclear sclerosis. (There was no
pseudoexfoliation in either eye.) An-
terior chambers were without either
cells or flare and were estimated by
Van Herick grading to be grade 3 in
both eyes. Intraocular pressure was
16 mmHg in both eyes at 3:30 p.m.
using Perkins applanation tonom-
etry. Dilated fundus examination was
performed. Cup-to-disc ratios were
0.8/0.8 OD and 0.7/0.7 OS. The
arterial-venous ratio was 2/3 in OU,
and the retinal vessels appeared nor-
mal. Maculas were clear in both eyes
although a foveal reflex was absent.
There were neither holes, tears nor
instances of  retinal detachment in
either eye. The patient was coun-
selled that a glaucoma work-up
would be in order. She said there
was no family history of  glaucoma,
but she was asked to inquire further
to be sure. The patient was asked
to book a follow-up for a check of
IOP, for gonioscopy and for another
look at the fundi. The patient de-
clined to be sent for visual field tests,
pachymetry, OCT and HRT. She was
also informed about the early cata-
racts and arcus. (The patient said she
had just had her cholesterol checked
and that it was normal.)
Follow-up #1 
After initially declining all further
testing and then taking an extended
vacation overseas, the patient
returned for a follow-up on
September 19, 2009. She stated that
her brother was in fact being treated
for glaucoma. Presenting distance
visual acuities through her glasses
(+3.25 - 2.00 × 065 OD and +3.25
- 2.00 × 120 OS) were 20/40 OD,
20/20 OS and 20/20 OU. Intra-
ocular pressure was 16 mmHg in
both eyes at 1:15 p.m. using Perkins
applanation tonometry. Gonioscopy
(Goldmann) was performed and did
not reveal any pathology. Scleral spur
was identified in all four quadrants
of  both eyes. Anterior chambers
were without either cells or flare.
Dilated fundus examination revealed
that cup-to-disc ratios were 0.8/0.8
OD and 0.7/0.7 OS. There was
no indication of  either optic nerve
drusen or nerve pallor in either eye.
The arterial-venous ratio was 2/3 in
OU, and the retinal vessels appeared
normal. Maculas were clear in both
eyes although a foveal reflex was
absent. The patient was scheduled
for pachymetry, OCT, HRT and a
visual field test.
Follow-up #2 
The patient rescheduled her follow-
up several times but finally had test-
ing done on January 6, 2010.
Visual field testing showed a large
inferior arcuate defect OU which
corresponded to the NFL superior
defect on both the OCT and HRT.
The visual field test was very reliable,
and GHT was outside normal limits
in both eyes. The signal strength
of  the OCT was a less than ideal 6
in each eye, probably due to media
opacities. Central corneal thickness
(CCT) was 510 µm OD and 515 µm
OS. The patient was informed that
she was a glaucoma suspect and was
scheduled for a consult with a
glaucoma specialist.
Follow-up #3  
The patient failed to appear for her
follow-up but finally returned for a
visual field at the glaucoma special-
ist’s office on July 29, 2010, prior to
the glaucoma consult. A repeatable
arcuate defect was confirmed in
each eye. At that visit the patient’s
corrected visual acuity was  20/40+2
OD and 20/30 OS. Her IOP was 16
mmHg in each eye at 11 a.m. using
Goldmann tonometry.
Follow-up #4 
The patient was then seen by the
glaucoma specialist on August 3,
2010. IOP at 12 p.m. was 16 mmHg
OU. Gonioscopy was performed,
and angles were found to be “open”
in both eyes. Cup-to-disc ratios were
0.8/0.6 OD and 0.8/0.6 OS and a
“superior rim notch” was noted OU.
OCT was repeated and confirmed
superior NFL damage in both eyes.
An “arcuate defect” in each eye was
identified based on the 24-2 Hum-
phrey visual field test (performed
July 29, 2010), which was consistent
with the area of  damage on OCT.
The following differential diagnosis
was considered in this case:
1. Physiological cupping has
neither field loss, progression of
cupping nor damage to NFL.18,31
Although cupping may be large,
the neuroretinal rim is healthy.10
2.Congenital anomaly of  the disc
is characterized by non-progres-
sive visual field defects.10,31
Examples include tilted discs,
colobomas and optic nerve pits.18
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which crossed the vertical midline. 
Gonioscopy and slit lamp exami-
nation did not reveal a secondary
cause for the suspected glaucoma. 
Therefore, the tentative diagnosis 
was primary open angle glaucoma 
likely of  the NTG subgroup 
because the pressure reading was 
within the statistical norm. However,
it is possible that, if  multiple read-
ings of  IOP had been taken over
a longer period and particularly at
night, there may either have been
times when the patient’s IOP was
elevated above 21 mmHg or have
been large diurnal fluctuations.
The glaucoma specialist pre-
scribed Travatan Z: 1 drop once
per day OU for our patient. She 
was to return for a follow-up in 
two months.
Follow-Up #5
The patient repeated HRT and 24-2
visual fields on October 13, 2010
at the glaucoma specialist’s office.
Her presenting visual acuities were
20/30-3 OD and 20/25-2 OS with
glasses. IOP was 10 mmHg OD and
14 mmHg OS at 4:08 p.m. using
Goldmann tonometry.
Follow-Up #6
The patient was subsequently seen
in the glaucoma specialist’s office
on October 19, 2010 for a consult.
The patient’s IOP was noted as
12 mmHg in both eyes at 3 p.m.
Pachymetry was 510 µm OD and
515 µm OS. “Adequate IOP con-
trol” was recorded in the assessment,
and a follow-up appointment was
scheduled for 6 months.
Follow-Up #7 
The patient was scheduled for
follow-up with the glaucoma special-
ist on April 20, 2011. She did not
appear for her appointment and did
not return either my office’s phone




Glaucoma affects 80 million people14
and is the second leading cause of
blindness worldwide.21,48 The preva-
lence of  glaucoma varies widely
around the globe, with the lowest
rate found among the First Nations
of  Alaska (0.006%) and the highest
among Caribbean people of  African
ancestry (7.1-8.8%).49
Two million people have glau-
coma in the U.S.,2 and the number
is expected to rise significantly.4
Rates are higher among Latinos than
among Caucasians, in comparison
with whom African Americans are
3-4 times more at risk.16 POAG is
the leading cause of  blindness in
African Americans.2 Normal ten-
sion glaucoma rates (among those
affected with glaucoma) appear high-
est in Japan.30
Risk Factors 
Glaucoma is a group of  optic neu-
ropathies with multiple risk factors,21
including increased cup-to-disc ratio,
thin central corneal thickness, either
African or Hispanic descent and the
presence of  an optic disc haemor-
rhage.2,13,15,36 Elevated IOP remains
the most significant risk factor for
glaucomatous progression.1,17 Optic
disc haemorrhage is critical since
it may precede visual field loss and
further optic nerve damage.16
Positive family history is also
an important risk actor.2,13,36,49 The
familial nature of  glaucoma has been
recognized for decades with up to
50% of  patients having a positive
family history.4 The prevalence of
glaucoma increases significantly in
those 60 and older.2
The roles of  diabetes15,16 and 
hypertension in glaucoma remain 
unclear.50,51 Controversially, some
recent studies suggest that, in 
patients with either pre-existing 
diabetes or cardiovascular disease, 
the daily use of  cholesterol drugs 
such as statins may reduce the risk 
of  POAG development.2
The relationship between glau-
coma and myopia is also still under
investigation,2,16 with some evidence
pointing to an increased risk of
glaucoma among myopes.19,36 The
LALES study suggested an indepen-
dent relationship between increased
axial length and glaucoma due to
weaker scleral support at the optic
nerve.16 There may be an associa-
tion between NTG and Raynaud’s
phenomenon, migraines and
hypotension.10,31,39 There are no en-
vironmental factors that are defini-
tively associated with POAG.49 IOP
remains the only known risk factor
that can be modified to decrease
chances of  disease progression.2
genetic Factors 
Clearly, there are genetic factors 
related to glaucoma.10 Less clear is 
the full extent of  the relationship; 
although some genes have been 
identified, over 90% remain a mys-
tery.4 To date, 22 genetic loci have
been linked to POAG, and 3 genes 
have been identified for POAG 
from the reported loci.21,30 Mabuchi
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et al recently concluded that SRBD1
gene polymorphism (a non-IOP-
related genetic factor) is associated
with both development of  NTG
and HTG POAG.30 Genes and some
environmental factors may affect the
rate of  ganglion cell apoptosis.49
which Changes happen First: 
Structural Or Functional?
Structural change precedes function-
al change in some glaucomatous eyes
but follows it in others.16 That some
ganglion cells may begin to malfunc-
tion before dying results in decreased
sensitivity without structural change.3
In other cases, where ganglion cell
redundancy is high, retinal nerve
fibre layer (RNFL) loss may precede
functional damage.11,38,39,42 In the
OHTS study, 60% of  patients who
converted to glaucoma had optic
disc changes before field loss.23,35,36
Both OHTS and EGPS showed
that, in many patients, structural
defects discovered with stereo
photos are detectable before re-
peatable SAP (standard automated
perimetry) functional defects.3
When SAP damage is detected first,
it may be that the patient started out
with more structure available to be lost
and therefore that the patient contin-
ues to be within the norm for struc-
ture.3 Functional glaucoma deficits
can occur before structural ones, but,
more commonly, structural damage
occurs before functional.5,11 The exact
mechanism of damage is not yet fully
understood.7,23,52
Diagnosis and management of
glaucoma are shifting from disease
staging to evidence-based risk  
assessment of  the patient.51 Risk 
factor calculators, such as the one 
that merged data from OHTS and
EGPS (http://ohts.wustl.edu/risk)
to create an online risk calculator for
clinicians, now help to predict a pa-
tient’s individual risk of  developing
glaucoma in the next five years.53
Because retinal ganglion cell
dysfunction and death characterize
glaucoma,20,54 detection is based on
identification of  either abnormali-
ties or changes to either the ONH
or the RNFL, either structural or
functional.26,54 As there is no true
gold standard for glaucoma diagno-
sis, progressive optic neuropathy has
been suggested as a definition for
use alongside functional testing.3,23
A purely functional view of
glaucoma may miss early glaucoma-
tous patients.3 The disease may more
comprehensively be defined accord-
ing to both functional and structural
criteria.26,27
Neuroprotection in glaucoma
Recent studies suggest the involve-
ment of  the immune system in 
glaucoma,12,20 but the neuroprotec-
tive and neurodestructive potenti-
alities of  the immune system make
its role unclear and sometimes 
contradictory.8,14 T-cell – medi-
ated immune response which is 
initially neuroprotective but goes 
unchecked12 may become autoim-
mune neurodegeneration.8
Damage to retinal ganglion cells 
could potentially be prevented by
targeting the mechanism behind 
neuronal destruction.20 Neuro-
protective agents used in neuro-
degenerative diseases such as ALS 
(amyotrophic lateral sclerosis) and 
Alzheimer’s disease are currently 
being evaluated for use in glau-
coma.14
Several antibodies have been
associated with glaucoma but no
definitive specific antibody has been
identified to screen for glaucoma.8
A recent study found that
BDNF (brain-derived neurotroph-
ic factor), a polypeptide growth-
factor known to develop and 
to preserve neurons,20 may be a 
useful biochemical marker for early
detection of  glaucoma.6 BDNF
crosses the blood-brain barrier 
and is found in lower concentra-
tions in the tears of  those with 
glaucoma.6 This may also become
a reliable, time-efficient and cost-
effective method for the screening 
and management of  the disease.6
Vaccinations which boost the im-
mune system such as ones being 
used to enhance neuroprotection 
in multiple sclerosis may become a 
promising therapy for glaucoma.12
Ocular hypertension and high 
Tension glaucoma 
Ocular hypertension (OH) is IOP
elevated above the normal range.13
OH can exist without causing either
damage to the nerve or vision loss
but is a key risk factor for glau-
coma.1 If  left untreated, roughly 1
in 10 patients with OH will develop
glaucoma in 5 years.1 The only
proven strategy to prevent POAG
progression is the use of  ocular
hypotensives among people with
OH.16,36,49 The decreasing of  IOP
lowers the rate of  conversion from
OH to POAG and slows its progres-
sion.2,15,36,50
In a glaucoma suspect, optic
nerve deterioration (confirmed
by either stereophoto, nerve fibre
analysis or visual field glaucomatous
changes) should be considered to
indicate a conversion to POAG.54
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This is why the establishment of  a
baseline through photography, imag-
ing and fields is critical.16
Normal Tension glaucoma 
Normal tension glaucoma (NTG) is
a form of  POAG10,13,18 where optic
nerve damage and corresponding
visual field defects occur 29,30 despite
apparently normal IOP.55 With
NTG, the etiological trigger – the
pathogenic process – simply takes
place at a lower IOP.31,33 Whenever
IOP in the individual is high enough
to initiate the disease process, the
pathophysiologic steps are the same
as in HTG.31 Chinese glaucoma spe-
cialists reached a consensus in 2008
that NTG is a subtype of  POAG
and the dividing line was IOP
greater than 21 mmHg.32
A neuro exam and MRI may be 
useful56 to differentiate between 
glaucoma and other types of  optic 
neuropathy.55 However, neuro-
opthalmic evaluation with neu-
roimaging does not seem to be 
necessary for all cases of  suspected 
NTG.31 
NTG is fundamentally the
same disease as POAG31, and the
treatment is the same,33 but some
features may be more prevalent in
NTG than HTG31,32 (splinter haem-
orrhages for example and CCT typi-
cally around 510 to 520 microns).18
The collaborative NTG study
showed that lowering the IOP by
30% did change the course of  the
disease in a majority of  patients.10,31,33
It is believed that non-IOP-
related factors are more important in
NTG,30 but recent findings may put
that reasoning into question. The
SRBD1 gene, which was considered
to be a non-IOP-related genetic
factor, is implicated in both NTG
and HTG.30 That HTG and NTG
run in the same families suggests
they either are the same or are
related conditions.31 A large propor-
tion of  glaucoma patients in Japan
suffer from NTG.37 (In a Japanese
study in the city of  Tajimi, 92% of
POAG suffers had NTG.)33 There is
no global consensus on the ques-
tion of  whether NTG and HTG are
simply subtypes of  POAG.32,56
Diagnostic Techniques 
Stereoscopic ONH photography is
a simple low-cost three-dimensional
image of  the ONH.10 In practice,
it is an accepted way of  document-
ing structural damage in glaucoma
suspects.15
An advantage of  subjective as-
sessment over quantitative analysis is
the inclusion of  some parameters of
the ONH (pallor and haemorrhages)
which contribute to a comprehen-
sive evaluation and are not quantifi-
able.3,38 The ONH has a wide range
of  normal variations; qualitative
variables have been shown to have
higher specificity than quantitative
parameters in separating glaucoma-
tous eyes from normal.3
Assessment of  the iridocorneal
angle by gonioscopy is key to ruling
out a secondary cause.2,15,16,57
For decades, Goldmann tonom-
etry has been the most accepted
way of  measuring IOP.19 Goldmann
assumed average corneal thickness
of  0.52 mm.19 That assumption
may lead to either under- or over-
estimations of  IOP with either
excessively thin or excessively thick
corneas.10,19,31
Advances in Diagnostic  
Techniques – CCT
OHTS’s discovery that lower than
average CCT was a risk factor for
glaucoma converted pachymetry into
a routine procedure in glaucoma as-
sessment.2,19,35,36,50
In both OHTS and EGPS, CCT
was the most important predictive
factor for conversion from OH to
glaucoma.35,36,47,58 CCT is no less
important in glaucoma suspects with
“normal” IOP. In those cases, fac-
tors unrelated to pressure are impor-
tant determiners of  progression.19
CCT as a risk factor is indepen-
dent of  IOP and possibly based on
biomechanical characteristics of  the
eye.47 CCT is not only important be-
cause of  the artefact of  Goldmann’s
assumption10,31 but because patients
with thinner corneas also have thin-
ner nerve fibre layers.47
Conversion to the “true” pres-
sure based on pachymetry is no 
longer advocated because there is 
no consensus on the conversion 
formula.16,47 (Conversion formulae
are widely believed to be oversim-
plifications of  a complex non-
linear multifactoral relation-
ship.)19,50  Instead of  converting, 
we now classify: either thick,
average or thin.50 Average CCT is 
approximately 545 µm.16,47 African 
Americans generally have thinner 
corneas,19,50 Caucasians’ corneas 
tend to be of  average thickness, 
and Asians’ corneas tend to be 
thicker.36,47 The OHTS study high-
lighted that, after adjustments were
made for larger baseline cup-to-
disk ratios, central corneal thick-
ness and not race was a statistically
significant predictor.36
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Recent studies have found that
there is considerable variation in 
the pachymetry readings measured 
by trained observers.35,47 Therefore, 
pachymetry should be repeated 
twice, and three times if  the first
two readings are different.35,47 CCT 
also changes over the course of
the day and over the course of  a 
lifetime;35 the cornea is thickest
in the morning due to corneal  
oedema and also thins with age.35
Imaging Technology and Retinal 
Nerve Fibre Analysis 
A new generation of  objective
(quantitative) imaging technologies
have been developed to measure
RNFL that go beyond photography,
which generally requires subjective
interpretation.11,37,39,54 To help the
clinician in the evaluation of  visual
function and structure, computer-
based imaging devices such as scan-
ning laser ophthalmoscopy (HRT),
scanning laser polarimetry (GDx)
and optical coherence tomography
(OCT) provide quantitative assess-
ment of  structural damage to the
optic disk and retinal nerve fibre
layer.3,7,9,10,11,15,16,37,41,59,60
HRT (Heidelberg retina tomo-
graph) is the commercially available
form of  confocal scanning laser
ophthalmoscopy.13,38 HRT uses a
laser to scan the retina at multiple
focal planes and creates a stack of  64
coronal planes.38 This provides the
examiner with optic disc topogra-
phy,38 a three-dimensional composite
image of  the ONH and posterior
segment.3,9,38,59 HRT can superimpose
baseline and follow-up images for au-
tomated detection of  ONH changes,
and existing machines may easily be
upgraded with newer software.3,9 The
new generation has a higher scan
rate and resolution59 and eliminates
a subjective component by eliminat-
ing the need for a contour line drawn
by the examiner.3,38,59 Scanning laser
polarimetry (GDx) uses polarized
light to measure the retinal nerve
fibre layer birefringence in order to
estimate tissue thickness.7,54,39  Media
opacities decreases its reliability but
the newer versions can compensate
for this more effectively.3 OCT em-
ploys the principles of  low-coherence
interferometry and is analogous to
ultrasound B-mode imaging but
using light – not sound –  to acquire
high-resolution images of  ocular
structures.7,11,54,59 The main limitations
of  time-domain OCT are low resolu-
tion and slow scan rate.40 The newest
OCT technology – spectral domain40
– collects all backscattered light
frequencies simultaneously.54 That
results in a faster scan rate40 and bet-
ter resolution,40 with each frequency
of  light representing a tissue depth.54
A new parameter was also introduced
for the OCT: signal strength (seven or
greater is needed for good quality).59
Ocular opacities can decrease the
reliability of  OCT as well.3
Multiple studies have found
structural imaging technology to be
at least as good as stereo photos in
their ability to help clinicians dif-
ferentiate between glaucomatous and
normal eyes.3,37,38,59,60 Studies have
not demonstrated the clear superior-
ity of  one imaging technique over
another.3,41
It is important to note that
the definition of  “normal” varies
with each technology (HRT, OCT,
GDx).59 In one study, both GDx
VCC and stratus OCT had similar
correlations at each clock-hour
segment, and both were useful in
early detection for patients with
preperimetric glaucoma.7
In another study, the diagnostic
imaging techniques outperformed
subjective assessment of  the optic
nerve by general opthalmolgists (but
not by glaucoma specialists, whose
expertise outperformed objective
techniques).59 All scans had bet-
ter sensitivity and specificity than
general ophthalmologists’ subjective
photo assessement of  ONH.59
In several studies, HRT was as
effective as stereophotos in estimat-
ing risk of  developing POAG in
ocular hypertensive subjects.3,38,60
Therefore, HRT can be used to
successfully differentiate ocular
hypertensives, normals and eyes
with glaucoma.3,9,38,60
The use of  scanning technology
in concert with subjective assess-
ment by either a general ophthalmol-
ogist or a glaucoma expert improved
identification of  glaucoma patients.59
This suggests that, particularly for
general ophthalmologists, measure-
ment of  RNFL provides an impor-
tant degree of  additive information
when combined with subjective
assessment.41,54,59 Scanning technol-
ogy should not replace observation
of  the optic nerve (or perimetry) but
complement it.11,39,54,59
Visual Field Testing 
Despite advances in glaucoma
diagnosis, visual field (VF) testing is
still important.3,5,34,43,44 It is critical to
include measurements both of  struc-
ture and of  function in the evalua-
tion of  glaucoma although they may
not correspond in the early stages
of  the disease.3,26,34 White-on-white
static automated perimetry is still the
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most commonly used method to 
clinically diagnose visual field loss 
(and monitor progression).5,16,37,39,42
It is now suggested that, due to 
the high variability of  results, VF
testing be repeated three times to 
confirm area of  loss.3 In OHTS, 
the majority of  VF abnormalities 
initially detected were not repeated 
on follow-up testing.3 SITA-SAP
(Swedish interactive threshold 
algorithm – standard automated 
perimetry) has become the standard
for clinical use with the Humphrey
visual field analyzer.3,34 SITA is a 
testing strategy that has decreased 
testing time to roughly five minutes
with no loss of  accuracy.3,42 GHT 
(glaucoma hemifield test) analyzes 
24-2 and 30-2 visual fields for pat-
terns typically found in glaucoma 
(such as vertical asymmetry).13
Newer technologies like FDT 
(frequency doubling technology)
and SWAP (short wavelength au-
tomated perimetry) may be helpful 
for early detection of  disease when 
SAP is normal but glaucoma is 
nevertheless suspected.37,42,43
FDT perimetry seems to have
promise as an effective and efficient
method of  detecting visual field
loss.7,16,43,44 It is portable, easier to use
and faster than SAP.42 FDT loses re-
liability with cataracts but has lower
test-retest variability compared to
SAP and SWAP.3,37 SWAP is selective
and highly sensitive to early damage
(up to 5 years earlier than SAP42).3,16
However, like FDT, it is vulnerable
to media opacities.3
Studies suggested that a combi-
nation of  field tests may increase
sensitivity to early damage without a
drop in specificity.42 Results of  tests
can be repeated either within a test
or across tests to look for evidence
of  damage to the same area;3,43
SITA-SAP may be combined with
SWAP, for example.
Advances in Therapeutic 
Options 
Medical treatment with ocular hypo-
tensives is the mainstay of  therapy,
particularly in the early stages of  the
disease.1,48 Beta-blockers, CAIs and
alpha-2 adrenergic agonists decrease
formation of  aqueous fluid while
prostaglandin analogues improve
outflow through the uveosceral
pathway.2,45,47
Prostaglandin analogues (PGAs),
the safest and most effective drugs
to date,1,47,61 have become the pre-
ferred first-line agents for glaucoma
management.10,46,47 Once daily dosing
optimizes convenience and increases
compliance.62 Patients respond dif-
ferently to each prostaglandin, none
of  which is universally better than
another.47
Hyperaemia, which is the most
common adverse effect of  PGAs
(and which has been found to
decrease compliance) occurs less
frequently in latanoprost.62 Timo-
lol (beta-blocker) monotherapy
produces far less hyperaemia but is
less effective than latanoprost and
bimotoprost.1 Out of  the PGAs,
latanoprost (which is associated with
less hyperaemia) may achieve the
best balance of  IOP efficacy and tol-
erability.1,47 There is no clear choice
of  adjunctive therapy with prosta-
glandins. Other classes are relatively
inefficacious with them.61
Contrary to the widely held belief,
IOP is actually highest at night.33,47
This is likely due to elevated epi-
scleral venous pressure which causes
a backup in the drainage system.47
Prostaglandins are better at prevent-
ing nocturnal spikes (due to mecha-
nism of  action) while beta-blockers
probably have poor IOP control at
night.47
Studies have shown Travatan’s
and Travatan Z’s duration of  ac-
tion exceeds their 24-hour dosing
schedule (up to 84 hours).46 The inci-
dence of  IOP varying with missed
doses, which has been associated
with glaucoma progression, thus
decreases.16,46,48
Travatan Z is the only PGA that
contains SofZia and not BAK as
a preservative.46,47 BAK reduces
TBUT and decreases epithelial cell
integrity, and that causes dry eye
and ocular surface inflammation.46,47
One study found ocular surface
disease is a problem in almost half
of  all glaucoma patients. The reduc-
tion of  BAK may be important in
glaucoma management.46,47 The
chronic subclinical inflammation can
cause surgical failure in those who
have filtration surgery.46,47 BAK-free
Travatan was found to be at least as
effective as original Travatan but bet-
ter for ocular surface disease.46
Management 
The goal of  glaucoma management
is to protect the patient’s vision and
quality of  life.34
IOP reduction should be at least
20 to 30% lower than where damage
occurred.1, 16, 22 The greater the initial
IOP, the greater the target reduc-
tion.1 Achieving these objectives may
require several medications, particu-
larly when reduction over 20% is
required.50
Determining the effectiveness of
IOP-lowering drugs is complicated
by a diurnal fluctuation of  up to
5 mmHg in normal populations with
no evidence of  pathology.1 Greater
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IOP fluctuations means greater risk
of  progression.16,34 The more the
IOP is lowered, the more likely that
the glaucoma progression will be
stopped.16
When pharmacological therapy
either fails or is not an option, vari-
ous surgical procedures are avail-
able either to increase outflow or
decrease inflow.10,63 Laser trabeculo-
plasty (incision-free) stimulates the
trabecular meshwork into func-
tioning more efficiently.2,13,16 Laser
trabeculoplasty was found to be at
least as efficacious as initial treat-
ment with topical medication in the
Glaucoma Laser Trial.63
Trabeculectomy is used when non-
incisional techniques fail.2,16 Drainage
implants, which are alternatives to
incisional techniques, shunt aqueous
humor to the subconjunctival space
(usually reserved for complicated
cases when trabeculectomy fails).2,16
Filtration surgery with cataract
removal is not as effective as filtration
surgery alone. Patients who need both
may want to delay cataract removal.16
Adherence 
Adherence to medications is a seri-
ous problem,15,16 with rates of  non-
compliance with glaucoma meds
sometimes soaring to 80% of  cases
in the literature.1,48 Lack of  consis-
tency in dosing can lead to either
sustained increases or fluctuations
in levels of  IOP.16 In either case,
the risk of  glaucoma progression
is increased.16,46 Non-compliance
may occur for many reasons. The
cost of  medication may be prohibi-
tive for the patient; the patient may
not be able to properly administer
dosage.16,48 Side effects may dissuade
a patient, and a patient may simply
fail to understand the importance
of  treatment and quit.16,48 The most
common reason cited is forgetful-
ness.48 Up to 50% of  patients dis-
continue chronic medications during
the first five months of  therapy
despite its importance in stopping
the progression of  glaucoma.62
The GAPS study showed that
37% of  patients experiencing hy-
peraemia with PGA will discontinue
treatment.1 Uninterrupted use of
glaucoma medication is relatively
rare but is better with latanoprost
than with other PGAs.62
Electronic monitoring is currently
the most objective method to track
patient adherence.48
The Future of POAg Diagnosis 
and Management 
A broadly accepted definition of
POAG24,26,27 in addition to a universal
and cost-effective screening protocol
is clearly needed to improve diagno-
sis and treatment.6 Detailed studies
on the time-frame from disease onset
to significant vision loss and blindness
need further investigation.51
Most definitions of  glaucoma are
based on visual field loss but recently
a definition incorporating progres-
sive optic disk change has been
suggested.3,27
Better hardware and software 
are needed to improve the diagnos-
tic value of  imaging technologies11 
and automated perimetry.43 Fu-
ture imaging technology includes 
polarization-sensitive OCT, which 
will allow more precise measure-
ment of  the RNFL.16,54 The next
generation of  OCT, swept source
(SS-OCT), will be even faster than 
spectral domain and will minimize 
motion artefacts.54 The high cost
of  imaging technology promotes 
the economic feasibility of  general
ophthalmologists receiving ongoing
training in optic disc glaucomatous
signs, particularly in developing
countries.59 Current tonometers
supply merely a snapshot, but future
models may be able to deliver, via
implant in the eye, 24 hours of
data (as with a Holter moniter).22
A new front in the fight against
glaucomatous damage may be
opened by drugs working through
an alternative to IOP-reduction.33,61
In particular, drugs which offer
neuroprotection (which shield the
optic nerve from damage) would
be revolutionary.12,14,20,61
Communication between optom-
etrists and ophthalmologists needs
to be improved; research shows that
both the letters of  referral to special-
ists and the responses to ODs leave
much to be desired.28 A recent study
showed that alarms, both audio
and visual, boast improved compli-
ance and a decreased proportion of
missed doses.48 Activities consistent
with overall health (such as exercise, a
diet high in fruits and vegetables and
the avoidance of  smoking) may be
suggested despite the present lack of
conclusive evidence.49 Lifestyle and
environment are factors requiring fur-
ther study. They may modify IOP-risk
and decrease the economic and visual
consequences of  POAG.49,51
Conclusion 
While much progress has occurred
in the diagnosis and management
of  POAG, the exact pathogenesis
and a cure remain elusive. This case
highlights the importance of  looking
beyond IOP and emphasizes the
application of  modern technology
and therapy in the management of
this disease.
d1071 new text.indd   43 12-04-18   11:25 AM
C a n a d i a n J o u r n a l o f o p t o m e t r y | r e v u e C a n a d i e n n e d ’ o p t o m é t r i evol 74  |  no 1  |  201244
References 
1. Orme M, Collins S, Dakin H, Kelly S, 
Loftus J. Mixed treatment comparison 
and meta-regression of  the efficacy and 
safety of  prostaglandin analogues and 
comparators for primary open-angle 
glaucoma and ocular hypertension. Curr 
Med Res Opin. 2010 Mar;26(3):511-28.
2. Hazin R, Hendrick AM, Kahook MY.
Primary open-angle glaucoma: diagnostic
approaches and management. J Natl Med
Assoc. 2009 Jan;101(1):46-50.
3. Sharma P, Sample PA, Zangwill LM, 
Schuman JS. Diagnostic tools for 
glaucoma detection and management. 
Surv Ophthalmol. 2008 Nov;53 
Suppl1:S17-32. 
4. Allingham RR, Liu Y, Rhee DJ. The 
genetics of  primary open-angle 
glaucoma: a review. Exp Eye Res. 2009 
Apr;88(4):837-44. 
5. Carreras FJ, Rica R, Delgado AV. 
Modeling the patterns of  visual field 
loss in glaucoma. Optom Vis Sci. 2011 
Jan;88(1):63-79. 
6. Ghaffariyeh A, Honarpisheh N, Heidari 
MH, Puyan S, Abasov F. Brain-derived 
neurotrophic factor as a biomarker in 
primary open-angle glaucoma. Optom 
Vis Sci.2011 Jan;88(1):80-5. 
7. Kim HG, Heo H, Park SW. Comparison 
of  scanning laser polarimetry and 
optical coherence tomography in 
preperimetric glaucoma. Optom Vis Sci. 
2011 Jan;88(1):124-9. 
8. Lee KJ, Jeong SM, Hoehn BD, Hong 
YJ, Lee SH. Valosin-containing protein 
is a novel autoantigen in patients 
with glaucoma. Optom Vis Sci. 2011 
Jan;88(1):164-72. 
9. Balasubramanian M, Bowd C, Weinreb 
RN, Zangwill LM. Agreement between 
the Heidelberg Retina Tomograph 
(HRT) stereometric parameters 
estimated using HRT-I and HRT-II. 
Optom Vis Sci. 2011 Jan;88(1):140-9. 
10. Friedman NJ Kaiser PK, Pineda R. The
Massachusetts eye and ear infirmary
illustrated manual of  ophthalmology. 3rd
Ed. Philadelphia: Elsevier, 2009:483-523.
11. Yoo YC, Park KH. Comparison of
optical coherence tomography and 
scanning laser polarimetry for detection 
of  localized retinal nerve fiber layer 
defects. J Glaucoma. 2010 Apr-
May;19(4):229-36. 
12. Cheung W, Guo L, Cordeiro MF. 
Neuroprotection in glaucoma: drug-
based approaches. Optom Vis Sci. 2008 
Jun;85(6):406-16. 
13. Kanski, JJ. Clinical ophthalmology: 
a systemic aproach 7th Ed. Oxford: 
Elsevier, 2011: 311-399, 785-811. 
14. Baltmr A, Duggan J, Nizari S, Salt 
TE, Cordeiro MF. Neuroprotection in 
glaucoma - Is there a future role? Exp 
Eye Res. 2010 Nov;91(5):554-66. 
15. American Academy of  Ophthalmology 
Glaucoma Panel. Preferred Practice 
Pattern® Guidelines. Primary Open-
Angle Glaucoma Suspect. San 
Francisco, CA: American Academy of
Ophthalmology; 2010. Available at: 
www.aao.org/ppp. 
16. American Academy of  Ophthalmology 
Glaucoma Panel. Preferred Practice 
Pattern® Guidelines. Primary Open-
Angle Glaucoma. San Francisco, CA: 
American Academy of  Ophthalmology; 
2010. Available at: www.aao.org/ppp. 
17. Kniestedt C, Punjabi O, Lin S, 
Stamper RL. Tonometry through the 
ages. Surv Ophthalmol. 2008 Nov-
Dec;53(6):568-91. 
18. Ehlers JP, Shah CP. The Wills Eye 
Manual: office and emergency room 
diagnosis and treatment of  eye disease. 
5th Ed. Baltimore: Lippincott Williams 
& Wilkins, 2008: 191-225. 
19. Lester M, Mete M, Figus M, Frezzotti P. 
Incorporating corneal pachymetry into 
the management of  glaucoma. J Cataract 
Refract Surg. 2009 Sep;35(9):1623-8. 
20. Danesh-Meyer HV. Neuroprotection 
in glaucoma: recent and future 
directions. Curr Opin Ophthalmol. 2011 
Mar;22(2):78-86. 
21. Jia LY, Tam PO, Chiang SW, Ding N, 
Chen LJ, Yam GH, Pang CP, Wang NL. 
Multiple gene polymorphisms analysis 
revealed a different profile of  genetic 
polymorphisms of  primary open-angle 
glaucoma in northern Chinese. Mol Vis. 
2009;15:89-98. 
22. Stamper RL. A history of  intraocular 
pressure and its measurement. Optom 
Vis Sci. 2011 Jan;88(1):16-28. 
23. Denniss J, Echendu D, Henson 
DB, Artes PH. Discus: investigating 
subjective judgment of  optic disc 
damage. Optom Vis Sci. 2011 
Jan;88(1):93-101. 
24. Miglior S, Guareschi M, Romanazzi 
F, Albe E, Torri V, Orzalesi N. the 
impact of  definition of  primary open-
angle glaucoma on the cross-sectional 
assessment of  diagnostic validity of
Heidelberg retinal tomography. Am J 
Ophthalmol. 2005 May;139(5):878-87. 
25. Swanson MW. The 97.5th and 99.5th 
percentile of  vertical cup disc ratio in 
the United States. Optom Vis Sci. 2011 
Jan;88(1):86-92. 
26. Boland MV, Quigley HA. Evaluation 
of  a combined index of  optic nerve 
structureand function for glaucoma 
diagnosis. BMC Ophthalmol. 2011 Feb 
11;11:6. 
27. Harwerth RS, Wheat JL, Fredette MJ, 
Anderson DR. Linking structure and 
function in glaucoma. Prog Retin Eye 
Res. 2010 Jul;29(4):249-71. 
28. Lockwood AJ, Kirwan JF, Ashleigh Z. 
Optometrists referrals for glaucoma 
assessment: a prospective survey of
clinical data and outcomes. Eye (Lond). 
2010 Sep;24(9):1515-9. 
29. Asrani S, Samuels B, Thakur M, Santiago 
C, Kuchibhatla M. Clinical Profiles of
Primary Open Angle Glaucoma versus 
Normal Tension Glaucoma Patients: 
A Pilot Study. Curr Eye Res. 2011 
May;36(5):429-35. 
30. Mabuchi F, Sakurada Y, Kashiwagi 
K, Yamagata Z, Iijima H, Tsukahara 
S. Association between SRBD1 and 
ELOVL5 gene polymorphisms and 
primary open angle glaucoma. 
Invest Ophthalmol Vis Sci. 2011 
Jun 28;52(7):4626-9. 
31. Anderson DR. Normal-tension 
glaucoma (Low-tension glaucoma). 
Indian J Ophthalmol. 2011 Jan;59 
Suppl:S97-101. 
32. Zhang L, Zhang YQ, Xu L, Yang H, 
Wu XS. [Is normal-tension glaucoma 
different from primary open-angle
glaucoma.]. Zhonghua Yan Ke Za Zhi. 
2011 Feb;47(2):105-108. 
33. Shields MB. Normal-tension glaucoma: 
is it different from primary open-angle 
d1071 new text.indd   44 12-04-18   11:25 AM
vol 74  |  no 1  |  2012C a n a d i a n  J o u r n a l  o f  o p t o m e t r y  |  r e v u e  C a n a d i e n n e  d ’ o p t o m é t r i e 45
glaucoma? Curr Opin Ophthalmol. 2008 
Mar;19(2):85-8. 
34. Gardiner SK, Demirel S, Johnson CA. 
Perimetric indices as predictors of  
future glaucomatous functional change. 
Optom Vis Sci. 2011 Jan;88(1):56-62. 
35. Brandt JD, Gordon MO, Beiser JA, Lin 
SC, Alexander MY, Kass MA; Ocular 
Hypertension Treatment Study Group. 
Changes in central corneal thickness 
over time: the ocular hypertension 
treatment study. Ophthalmology. 2008 
Sep;115(9):1550-1556. 
36. Gordon MO, Beiser JA, Brandt JD, 
Heuer DK, Higginbotham EJ, Johnson 
CA, Keltner JL, Miller JP, Parrish RK 
2nd, Wilson MR, Kass MA. The Ocular 
Hypertension Treatment Study: baseline 
factors that predict the onset of  primary 
open-angle glaucoma. Arch Ophthalmol. 
2002 Jun;120(6):714-20; discussion 829-
30. 
37. Nomoto H, Matsumoto C, Takada S, 
Hashimoto S, Arimura E, Okuyama 
S, Shimomura Y. Detectability of  
glaucomatous changes using SAP, FDT, 
flicker perimetry, and OCT. J Glaucoma. 
2009 Feb;18(2):165-71. 
38. Alencar LM, Bowd C, Weinreb RN, 
Zangwill LM, Sample PA, Medeiros 
FA. Comparison of  HRT-3 glaucoma 
probability score and subjective 
stereophotograph assessment for 
prediction of  progression in glaucoma. 
Invest Ophthalmol Vis Sci. 2008 
May;49(5):1898-906. 
39. Alencar LM, Zangwill LM, Weinreb 
RN, Bowd C, Vizzeri G, Sample PA, 
Susanna R Jr, Medeiros FA. Agreement 
for detecting glaucoma progression with 
the GDx guidedprogression analysis, 
automated perimetry, and optic disc 
photography.Ophthalmology. 2010 
Mar;117(3):462-70. 
40. Rao HL, Zangwill LM, Weinreb RN, 
Sample PA, Alencar LM, Medeiros 
FA. Comparison of  different spectral 
domain optical coherence tomography 
scanning areas for glaucoma diagnosis. 
Ophthalmology. 2010 Sep;117(9):1692-9. 
41. Pueyo V, Polo V, Larrosa JM, Ferreras 
A, Alias E, Honrubia FM. Ability 
of  different optical imaging devices 
to discriminate between healthy and 
glaucomatous eyes. Ann Ophthalmol 
(Skokie). 2009 Summer;41(2):102-8. 
42. Alencar LM, Medeiros FA. The role 
of  standard automated perimetry and 
newer functional methods for glaucoma 
diagnosis and follow-up. Indian J 
Ophthalmol.2011 Jan;59 Suppl:S53-8. 
43. Fogagnolo P, Rossetti L, Ranno 
S, Ferreras A, Orzalesi N. Short-
wavelength automated perimetry 
and frequency-doubling technology 
perimetry in glaucoma. Prog Brain Res. 
2008;173:101-24. 
44. Johnson CA, Wall M, Thompson HS. A 
history of perimetry and visual field testing. 
Optom Vis Sci. 2011 Jan;88(1):8-15. 
45. Susanna R Jr, Medeiros FA. The pros 
and cons of  different prostanoids in the 
medical management of  glaucoma. Curr 
Opin Ophthalmol. 2001 Apr;12(2):149-56. 
46. Gross RL, Peace JH, Smith SE, Walters 
TR, Dubiner HB, Weiss MJ, Ochsner 
KI. Duration of  IOP reduction with 
travoprost BAK-free solution. J 
Glaucoma. 2008 Apr-May;17(3):217-22. 
47. Sowka J. The four Ps of  glaucoma. Rev 
Optom 2010 Nov 15:66-71. 
48. Ho LY, Camejo L, Kahook MY, 
Noecker R. Effect of  audible and visual 
reminders on adherence in glaucoma 
patients using a commercially available 
dosing aid. Clin Ophthalmol. 2008 
Dec;2(4):769-72. 
49. Pasquale LR, Kang JH. Lifestyle, 
nutrition, and glaucoma. J Glaucoma. 
2009 Aug;18(6):423-8. 
50. Rhee DJ. Preventing glaucoma in a high-
risk population: impact and observations 
of  the Ocular Hypertension Treatment 
Study. Arch Ophthalmol. 2009 
Feb;127(2):216-8. 
51. Weinreb RN, Medeiros F. Risk 
assessment for glaucoma. Open 
Ophthalmol J. 2009 Sep 17;3:30-1. 
52. Shafi A, Swanson WH, Dul MW. 
Structure and function in patients with 
glaucomatous defects near fixation. 
Optom Vis Sci. 2011 Jan;88(1):130-9. 
53. Ocular Hypertension Treatment Study 
Group; European Glaucoma Prevention 
Study Group, Gordon MO, Torri V, 
Miglior S, Beiser JA, Floriani I, Miller JP, 
Gao F, Adamsons I, Poli D, D’Agostino 
RB, Kass MA. Validated prediction 
model for the development of  primary 
open-angle glaucoma in individuals with 
ocular hypertension. Ophthalmology. 
2007 Jan;114(1):10-9. 
54. Townsend KA, Wollstein G, Schuman 
JS. Imaging of  the retinal nerve fibre 
layer for glaucoma. Br J Ophthalmol. 
2009 Feb;93(2):139-43 
55. Dumitrica DM, Stefan C. [Normotensive 
glaucoma]. Oftalmologia. 2008;52(1):31-5. 
56. Potop V, Dumitrache M, Ciocalteu 
A.[Normal tension glaucoma]. 
Oftalmologia. 2010;54(2):11-4. 
57. Alward WL. A history of  gonioscopy. 
Optom Vis Sci. 2011 Jan;88(1):29-35. 
58. Elsheikh A, Alhasso D, Gunvant P, 
Garway-Heath D. Multiparameter 
correction equation for Goldmann 
applanation tonometry. Optom Vis Sci. 
2011 Jan;88(1):102-12.
59. Vessani RM, Moritz R, Batis L, 
Zagui RB, Bernardoni S, Susanna R. 
Comparison of  quantitative imaging 
devices and subjective optic nerve head 
assessment by general ophthalmologists 
to differentiate normal from 
glaucomatous eyes. J Glaucoma. 2009 
Mar;18(3):253-61. 
60. Weinreb RN, Zangwill LM, Jain S, Becerra 
LM, Dirkes K, Piltz-Seymour JR, Cioffi 
GA, Trick GL, Coleman AL, Brandt JD, 
Liebmann JM, Gordon MO, Kass MA; 
OHTS CSLO Ancillary Study Group. 
Predicting the onset of  glaucoma: the 
confocal scanning laser ophthalmoscopy 
ancillary study to the Ocular Hypertension 
Treatment Study. Ophthalmology. 2010 
Sep;117(9):1674-83. 
61. Realini T. A history of  glaucoma 
pharmacology. Optom Vis Sci. 2011 
Jan;88(1):36-8. 
62. Hahn SR, Kotak S, Tan J, Kim E. 
Physicians’ treatment decisions, patient 
persistence, and interruptions in the 
continuous use of  prostaglandin therapy 
in glaucoma. Curr Med Res Opin. 2010 
Apr;26(4):957-63. 
63. Razeghinejad MR, Spaeth GL. A 
history of  the surgical management 
of  glaucoma. Optom Vis Sci. 2011 
Jan;88(1):39-47. 
d1071 new text.indd   45 12-04-18   11:25 AM
